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External beam radiotherapy is being used regularly to treat the breast malignancy post-
operatively. The contribution of the collimator leakage and scatter radiation dose to
contralateral breast is of concern because of high radio sensitivity of breast tissue for
carcinogenesis. This becomes more important when the age of breast cancer breast patient
is younger than 45 years and therefore the contralateral breast must be treated as organ at
risk. Quantification of contralateral dose during primary breast irradiation is helpful to
estimate the risk of radiation induced secondary breast malignancy. In present study
contralateral breast dose was measured in forty cancer breast patients undergoing external
beam therapy by cobalt-60 teletherapy machine. Post-operative radiotherapy was delivered
by medial and lateral tangential fields daily, in addition to supraclavicular field with
200 cGy per fraction to a total dose of 5000 cGy in 25 fractions. The detectors of rainbow
dosimeter were employed for these measurements.
The dose at the contralateral breast measured by a rainbow dosimeter for tangential
fields was between 5.34e6.40% whereas for supraclavicular field it is 1.2e1.75% of the
dose. The contribution due to the medial tangential field is almost twice as that due to
lateral tangential field so that maximum dose which contributes contralateral breast dose
is due to medial tangential field. The goal of this investigation was to quantify the radi-
ation dose to the contralateral breast after radiotherapy for primary breast cancer.
Rainbow dosimetry is easy, accurate and convenient method to measure the contralateral
breast dose.
Copyright © 2014, The Egyptian Society of Radiation Sciences and Applications. Production
and hosting by Elsevier B.V. All rights reserved..
(M. Mohib-ul Haq).
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Breast cancer is the most common cancer among women,
worldwide. It is probably the most feared cancer in women
because of its psychological impacts. It affects the perception
of sexuality and self image to a degree far greater than any
other cancer. It is becoming number one killer in females.
Therefore it has become an increasingly important subject of
research all over the world. Globally, every 3 minutes a
woman is diagnosed with breast cancer, amounting to one
million cases annually. According toWorld Cancer Report, the
incidence could go up by 50% to 1.5 million by 2020 (Mahavir&
Babita, 2013). In India and other developing countries, breast
carcinoma ranks second only to carcinoma of cervix among
women, however the incidence of breast cancer is on the rise
and may become the number one cancer in females in the
near future. It is estimated that at present approximately
80,000 cases occur annually in India and by 2030 the number
of new cases of breast cases will approximately be 200,000 per
year (Datta, Choudhuri, Guha, & Biswas, 2012; Gupta, Sharma,
& Verma, 2002)
Breast cancer is most curable when detected at its earlier
stages. Radiotherapy plays an essential role in the manage-
ment of breast cancer and many studies have shown better
survival of patients after mastectomy followed by radio-
therapy (Keyvan, Nazli, Shadi, & Alireza, 2013). Although ra-
diation is a cancer healer, but it also carcinogenic, therefore it
has been described as a “two edged sword”. Women with
breast cancer have three-to four-fold increased risk of devel-
oping a new primary cancer in the contralateral breast, as
compared with the risk of a first primary breast cancer among
other women (Adami, Bergstrom, & Hansen, 1985; Harvey &
Brinton, 1985). In general, Radiotherapy for breast cancer
after mastectomy and breast-conserving surgery include
chest wall and for patients with regional lymph node
involvement, the supraclavicular region should be regularly
irradiated (Fisher et al., 2002). For patients receiving irradia-
tion to both the chest wall and supraclavicular area, the irra-
diation field area is generally divided into two groups by the
baseline of the lower edge of the subclavian head: one pair of
tangential beams to cover the chest wall and interior beam to
cover the upper supraclavicular area as shown in Fig. 1. DuringFig. 1 e Anterior view of treatment fields of the patient
positions.external beam therapy of malignant breast, the contralateral
breast receives radiation due to leakage from collimator and
scatter from primary beam. Breast is highly radiosensitive
tissue for radiation induced secondmalignancy and is ofmore
concern for female younger than 45 years of age receiving
radiotherapy for breast malignancy. Boice, Land, Shore,
Norman, and Tokunaga (1979) have reported that incidence
of dose received by the contralateral breast and the latent
period is over 10 years. Several investigators (Frass, Roberson,
& Lichter, 1985; Kelly, Wang, Chu, & Hartselle, 1996; Muller &
Kalokhe, 1990) have measured the contralateral breast dose
on Anderson female phantom/Rando phantom observed that
the scatter dose to contralateral breast during medial
tangential and supraclavicular field is quite high and some
times of the order of 500 cGy for 5000 cGy primary breast dose.
The quantification of the contralateral breast especially dur-
ing treatment of diseased breast by external beam is very
important, as the scatter contribution will be more.
In the present study, measurement of contralateral breast
dose is done by using rainbow dosimeter with solid state de-
tectors because of small size, high sensitive ability to record
very small doses and energy independent response. The de-
tectors of rainbow dosimeter were employed for the mea-
surement of radiation doses to contralateral breast. The
dosimeter has applications for relatively low doses and dose-
rate independent up to 108 Gy s1. The system is also inde-
pendent of relative humidity and can be used over a broad
temperature (0 to 5 C). The integrated radiation effect that is
used for themeasurement is the shift in threshold voltage due
to trapped charge in the multilayered device. This threshold
voltage is evaluated in the measurement of the channel
(drain) current as a function of gate voltage at a constant
supply voltage to the device.2. Materials and methods
In present study contralateral breast dose was measured in
forty breast cancer patients undergoing external beam ther-
apy by cobalt-60 teletherapy machine. In radiotherapy for
breast cancer, the chest wall was treated with medial and
lateral tangential fields daily. Total Dose of 5000 cGy is given in
25 fractions to the chest wall with a dose of 200 cGy per frac-
tion. Patients are usually placed in the supine position on an
angled breast boardwith one or both arms stretched above the
head. The position of the patient is kept similar in treatment
and simulation. The patient is placed on an angled breast
board because the sternum slope and chest wall slope is
modified. Tangential fields must cover the breast and edges of
the field are shaped based on patients' anatomy. In addition to
these tangential fields, a supraclavicular field is also given
with radiation dose of 5000 cGy and fraction dose of 200 cGy in
25 fractions.
Three detectors were put on the surface of the skin of
contralateral breast, one at the level of nipple and two other
detectorswere placed 3 cmaway from the nipple on both sides
along themiddle line for each field as shown in Fig. 2.Themost
widely accepted technique for whole-breast irradiation is the
tangential field technique, inwhich the entire breast and chest
wall, with a small portion of lung, is included in the irradiated
Fig.2 e Schematic representation of the detector during
breast treatment at ‘A’, ‘B’ and ‘C’.
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of the percentage of ipsilateral lung volume treated by the
tangential fields is central lungdistance (CLD),which is defined
as the perpendicular distance from the posterior tangential
edge to the posterior part of the anterior chest wall at the
center of the field. A CLD of 1.5 cm predicts that approximately
6% of the lung is in the irradiation field; when CLD is increased
to 3.5 cm, approximately 26% of the lung is included, which
may augment the risk of developing pneumonitis. When the
CLD is >3 cm, particularly in the left breast, a significant vol-
ume of the heart will be irradiated as well. The most common
schedule for breast irradiation is to deliver 50 Gy to the whole
breast over 5 to 6 weeks with daily doses of 1.8 to 2 Gy. Radio-
therapy should be initiatedwithout a longdelay after surgery if
chemotherapy is not delivered. A delay longer than 3 months
has been associated with decreased survival.3. Results
The goal of this investigation was to quantify the radiation
dose to the contralateral breast after radiotherapy for primary
breast cancer. The contribution of contralateral breast dose
because of various treatment fields is given in Table 1. It is
observed that the contribution to contralateral breast dose
due to for tangential fields is between 5.34e6.40% whereas for
supraclavicular field it is 1.2e1.75% of the dose as shown in
Fig. 3. The contribution due to the medial tangential field is
almost twice as that due to lateral tangential field. The lateral
tangential field enters laterally and may be contributing to
internal scatter, which is very difficult whereas the medial
tangential field is close to the contralateral breast and hence
the scatter and the collimator contribution is more. Age, type
andmode of the surgery of different breast cancer patients are
mentioned in Table 2.4. Discussion
Among the 40 patients in our study, the surface doses recor-
ded at the contralateral breast in the range for tangential fields
between 5.34e6.40% whereas for supraclavicular field it is
1.2e1.75% of the dose. We found that the following factors are
likely to increase the dose to the contralateral breast: A short perpendicular distance from the contralateral breast
surface to the geometric beam edge increases the dose at
the surface. A short perpendicular distance can be caused
by a shallow medial gantry angle or a large, protruding
breast. A combination of both is the least favourable.
 It is observed that the contribution to contralateral breast
dose due to all the fields. The contribution due to the
medial tangential field is almost twice as that due to lateral
tangential field. The lateral tangential fields enter laterally
and may be contributing to internal scatter, which is very
difficult whereas the medial tangential field is close to the
contralateral breast and hence the scatter and the colli-
mator contribution is more.
Dose to contralateral breast as a result of radiotherapy of
breast should not be ignored in radiotherapy and more so in
patients younger than 45 years. The breast tissue is highly
sensitive and therefore the contralateral breast must be
regarded as organ at risk while planning for radiotherapy. Ra-
diation carcinogenesis is stochastic process where probability
of cancer induction increases with dose and there is no
threshold dose (Hall & Giaccia, 2006). Many researchers have
reported thecontralateral breastdose; somereported resultsof
direct measurement on patients, some reported measure-
mentsonphantomandsomegave thefigures fromcalculation.
Gao, Fisher, and Emami (2003) found a relative risk of 1.32
and 1.15, respectively, for second cancer induction in the
contralateral breast of women patients whose ages were
below 45 years and over 55 years at the time of diagnosis. In a
15-year follow-up, Obedian, Fischer, and Haffty (2000) re-
ported a 10% increase in contralateral breast cancer rate in
patients who had radical mastectomy under the age of 45 and
received a total dose of 46e54 Gy to the involved breast. This
increasewas small compared to a 7% increase in breast cancer
in the control unirradiated group.
Boice, Harvey, Blettner, Storall, and Flannery (1992) have
conducted case control study in cohort of 41,109 women
diagnosed with breast cancer and analyzed the records. They
found mean contralateral breast to be 282 cGy with
maximum of 710 cGy and relative overall increase in risk of
contralateral breast malignancy due to treatment of primary
by radiation to be 1.19. However, the risk of second malig-
nancy in the contralateral breast was 1.59, significantly high,
in patients who underwent radiotherapy at younger age then
45 years for primary breast malignancy. This indicates high
risk for younger patients. Muller and Kalokhe (1994) have
advocated covering of contralateral breast with thin lead
sheet to reduce the scattered contribution to contralateral
breast skin though little can be done to reduce the dose from
the lateral tangential field as the dose is caused by internal
body scatter. They used 4 mm thick commercially available
vinyl coated flexible lead shield containing lead powder of
1 mm equivalent lead density to cover the contralateral
breast and found that the contralateral dose is reduced by 3
fold from 15% to 5%. Kelly et al. (1996) reported a study of
evaluation of four different breast treatment techniques with
6 MV linac beam to compare the radiation dose to the
contralateral breast. They have done the dose measurement
of Rando Phantom using TLD and used four different tech-
niques of half beam with custom blocks, half beam using
Table 1 e Contralateral breast dose because of various treatment fields.















1. 4.1 8.3 12.4 6.20 ±2.49 3.0 1.50 ±1.22
2. 4.2 8.5 12.7 6.35 ±2.52 3.1 1.55 ±1.24
3. 3.9 8.0 11.9 5.95. ±2.44 2.8 1.40 ±1.18
4. 4.0 8.1 12.1 6.05 ±2.46 2.9 1.45 ±1.20
5. 3.7 7.8 11.5 5.75 ±2.39 2.7 1.35 ±1.16
6. 4.2 8.5 12.7 6.35 ±2.52 3.0 1.50 ±1.22
7. 4.1 8.2 12.3 6.15 ±2.48 2.9 1.45 ±1.20
8. 3.8 7.9 11.6 5.80 ±2.40 2.8 1.40 ±1.18
9. 4.0 8.1 12.1 6.05 ±2.45 3.0 1.50 ±1.22
10. 3.9 8.0 11.9 5.95 ±2.43 2.9 1.45 ±1.20
11. 4.3 8.5 12.8 6.40 ±2.53 3.4 1.70 ±1.30
12. 4.1 8.2 12.3 6.15 ±2.48 3.1 1.55 ±1.24
13. 4.2 8.3 12.5 6.25 ±2.50 3.2 1.60 ±1.26
14. 3.8 7.9 11.7 5.85 ±2.41 2.9 1.45 ±1.20
15. 3.5 7.6 11.1 5.55 ±2.35 2.5 1.25 ±1.12
16. 4.0 8.1 12.1 6.05 ±2.46 2.9 1.45 ±1.20
17. 3.7 7.7 11.4 5.70 ±2.38 2.5 1.25 ±1.12
18. 4.1 8.3 12.4 6.20 ±2.49 2.7 1.35 ±1.16
19. 3.9 8.0 11.9 5.95 ±2.44 2.8 1.40 ±1.18
20. 4.2 8.6 12.8 6.40 ±2.53 2.9 1.45 ±1.20
21. 4.1 8.3 12.4 6.20 ±2.49 3.1 1.55 ±1.24
22. 3.8 7.8 11.6 5.80 ±2.40 2.8 1.40 ±1.18
23. 4.3 8.4 12.7 6.35 ±2.52 3.2 1.60 ±1.26
24. 4.0 8.1 12.1 6.05 ±2.46 2.8 1.40 ±1.18
25. 3.5 7.2 10.7 6.35 ±2.52 2.4 1.20 ±1.09
26. 4.2 8.4 12.6 6.30 ±2.51 3.1 1.55 ±1.24
27. 4.1 8.3 12.4 6.20 ±2.49 2.8 1.40 ±1.18
28. 3.9 8.0 12.9 5.95 ±2.44 3.1 1.55 ±1.24
29. 3.8 7.9 11.7 5.85 ±2.41 2.7 1.35 ±1.16
30. 4.1 8.2 12.3 6.15 ±2.48 3.2 1.60 ±1.26
31. 4.2 8.5 12.7 6.35 ±2.52 2.8 1.40 ±1.18
32. 3.7 7.7 11.4 5.70 ±2.38 3.0 1.50 ±1.22
33. 3.9 7.9 11.8 5.90 ±2.43 3.1 1.55 ±1.24
34. 4.1 8.1 12.2 6.10 ±2.47 3.2 1.60 ±1.26
35. 4.2 8.3 12.5 6.25 ±2.50 3.5 1.75 ±1.32
36. 3.8 7.8 11.6 5.80 ±2.40 2.8 1.40 ±1.18
37. 3.9 8.0 11.9 5.95 ±2.44 3.0 1.50 ±1.22
38. 3.7 7.6 11.3 5.65 ±2.37 2.7 1.35 ±1.16
39. 4.0 8.1 12.1 6.05 ±2.46 2.9 1.45 ±1.20
40. 4.2 8.3 12.5 6.25 ±2.50 3.1 1.55 ±1.24
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collimator jaws with custom blocks and isocentric technique
with non-divergent posterior border. They observed higher
contralateral breast dose during medial field with wedge and
lowest dose with asymmetric jaws and no medial wedge or
block. Bhatnagar, Heron, Deutch, Brandner, and Kalnicki
(2006) reported comparison of contralateral breast dose
during primary breast irradiation using intensity modulated
radiotherapy (IMRT) and conventional tangential field tech-
nique. They have treated 36 patients of breast malignancy
with IMRT and 8 with 3-D technique using tangential field
with wedge and measured contralateral breast dose during
treatment using TLD. They observed the contralateral breast
dose of 7.74 ± 2.35% of primary breast dose (5000 cGy) in
IMRT treatment planning and 9.74 ± 2.04% of primary breast
dose during conventional tangential field technique i.e.,
about 20% reduction in contralateral breast dose with IMRT
as compared to conventional tangential treatment with
wedge. Chougule (2007) suggested that use TLD discs tomeasure the contralateral breast dose during half beam
block for patients treated with primary breast irradiation on
teletherapy unit.
Bhatnager et al. (2004) have studied the effect of breast size
on scatter dose to contralateral breast. They have treated 65
patients of breast cancer using 6 MV photon with IMRT tech-
nique and measured contralateral breast dose using TLD. The
primary breast size volume was calculated by planning sys-
tem fromCT slices. They found themean contralateral dose of
7.2% of primary breast dose (5000 cGy) and found that the
contribution to contralateral breast dose is strongly depen-
dent on primary breast size of the patient. Therefore it became
of more concern in young breast cancer patients with bulky
protuberant breast.
Wahaba and Reham (2009) proposed to use 2-mm lead
shield during breast radiation therapy in order to achieve an
effective reduction in contralateral breast dose. Hooning et al.
(2008) reported that young patients with breast cancer irradi-
ated with breast tangential experience increased risk of
Table 2 e Age, type and mode of surgery of different breast cancer patients.
S. No Age of the patient Prescribed dose (Gy) Type of the cancer Mode of the surgery
1. 58 50 Invasive ductal carcinoma Mastectomy
2. 39 50 Invasive ductal carcinoma Radical mastectomy
3. 65 50 Invasive ductal carcinoma Mastectomy
4 62 50 Invasive ductal carcinoma Mastectomy
5 67 50 Invasive ductal carcinoma Mastectomy
6 37 50 Invasive ductal carcinoma Radical mastectomy
7. 60 50 Invasive ductal carcinoma Mastectomy
8. 66 50 Invasive ductal carcinoma Mastectomy
9. 61 50 Invasive ductal carcinoma Mastectomy
10. 60 50 Invasive ductal carcinoma Mastectomy
11. 38 50 Invasive ductal carcinoma Radical mastectomy
12. 62 50 Invasive ductal carcinoma Mastectomy
13. 59 50 Invasive ductal carcinoma Mastectomy
14. 66 50 Invasive ductal carcinoma Mastectomy
15 64 50 Invasive ductal carcinoma Mastectomy
16 60 50 Invasive ductal carcinoma Mastectomy
17 65 50 Invasive ductal carcinoma Mastectomy
18 58 50 Invasive ductal carcinoma Mastectomy
19 64 50 Invasive ductal carcinoma Mastectomy
20 37 50 Invasive ductal carcinoma Radical mastectomy
21 60 50 Invasive ductal carcinoma Mastectomy
22 66 50 Ductal carcinoma Mastectomy
23 35 50 Invasive ductal carcinoma Radical mastectomy
24 59 50 Invasive ductal carcinoma Mastectomy
25 67 50 Invasive ductal carcinoma Mastectomy
26 36 50 Invasive ductal carcinoma Radical mastectomy
27 50 50 Invasive ductal carcinoma Mastectomy
28 58 50 Invasive ductal carcinoma Mastectomy
29 63 50 Invasive ductal carcinoma Mastectomy
30 59 50 Invasive ductal carcinoma Mastectomy
31 37 50 Invasive ductal carcinoma Mastectomy
32 63 50 Invasive ductal carcinoma Mastectomy
33 65 50 Ductal carcinoma Mastectomy
34 60 50 Invasive ductal carcinoma Mastectomy
35 57 50 Invasive ductal carcinoma Mastectomy
36 66 50 Invasive ductal carcinoma Mastectomy
37 65 50 Invasive ductal carcinoma Mastectomy
38 63 50 Invasive ductal carcinoma Mastectomy
39 61 50 Invasive ductal carcinoma Mastectomy
40 59 50 Ductal carcinoma Mastectomy




























Fig. 3 e Dose calculation for different patients at various geometries.
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family in story of breast cancer. Alzoubi, Kandaiya, Shukri,
and Elsherbieny (2010) found that breast and chest wall
radiotherapy treatment using 6-MV photons and measured
contralateral breast dose at the surface fell sharply with dis-
tance from the field edge. The average ratio of the measure-
ment to the calculated contralateral breast dose using the
pencil beam algorithm at surface was approximately 53%.5. Conclusion
Rainbow dosimetry is very easy, most convenient and reason-
ably accurate method to measure the dose to contralateral
breast. Dose to the contralateral breast as a result of radio-
therapy of breast should not be ignored in radiotherapy and
more so in patients younger than 45 years. Contralateral breast
dose increases with increase in size/area of the primary breast
to be treated as well as the patient thickness. The contralateral
breast doses to patients with lumpectomy are much higher
than those with mastectomy for the same lateral separation.
The use of half beam block instead of asymmetric collimator
inCo-60machine increases thedose tocontralateralbreastdose.
Thehalf beamblocker lies comparativelyclose to thepatientand
thereby increases dose to the contralateral breast. The dose to
the contralateral breast is mainly due to scatter and trans-
missionof radiation throughhalf beamblocker. Thescatterdose
received by the contralateral breast can be reduced by strapping
the contralateral breast with paper tape. In addition to this the
dose due to transmission can be also reduced by strapping the
contralateral breast away from the collimated beam, this can be
donemainly if the patient has pendulum breast.
In case of the left breast, a significant volume of the heart
will be irradiated as well. The amount of the heart volume in
the tangential field associated with the development of car-
diovascular disease, techniques like the addition of a medial
portal with the use of electrons should be considered, espe-
cially in patients with wide tangential fields and with an
increased central lung distance because of large breasts. A
significant dose inhomogeneity is predictable, which could
result in less satisfactory cosmetic outcomes. To minimize
this problem, 10e15 megavolt (MV), high-energy X-rays may
be needed. The breast tissue is highly sensitive and therefore
the contralateral breast must be regarded as organ at risk
(sensitive organ) while planning for radiotherapy.r e f e r e n c e s
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